Cargando…

Association between Equol Production Status and Nonalcoholic Steatohepatitis

Equol is a metabolite of daidzein, a major soybean isoflavone with estrogenic and antioxidant activities. As the production of equol depends on the presence of certain members of the intestinal microflora, not all individuals can produce equol. We examined the relationship between NASH histological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akahane, Takemi, Kaya, Daisuke, Noguchi, Ryuichi, Kaji, Kosuke, Miyakawa, Haruna, Fujinaga, Yukihisa, Tsuji, Yuki, Takaya, Hiroaki, Sawada, Yasuhiko, Furukawa, Masanori, Kitagawa, Koh, Ozutsumi, Takahiro, Kawaratani, Hideto, Moriya, Kei, Namisaki, Tadashi, Yoshiji, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585044/ https://www.ncbi.nlm.nih.gov/pubmed/34769332 http://dx.doi.org/10.3390/ijms222111904

Ejemplares similares

Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis
por: Tsuji, Yuki, et al.
Publicado: (2020)

Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2020)

Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis
por: Nishimura, Norihisa, et al.
Publicado: (2021)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
por: Ozutsumi, Takahiro, et al.
Publicado: (2020)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
por: Kaji, Kosuke, et al.
Publicado: (2020)

Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study
por: Akahane, Takemi, et al.
Publicado: (2020)

Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study
por: Kitagawa, Koh, et al.
Publicado: (2022)

TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats
por: Kaya, Daisuke, et al.
Publicado: (2019)

Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males
por: Akahane, Takemi, et al.
Publicado: (2020)

The Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria
por: Takaya, Hiroaki, et al.
Publicado: (2021)

Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2020)

Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis
por: Kitagawa, Koh, et al.
Publicado: (2021)

Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor
por: Furukawa, Masanori, et al.
Publicado: (2021)

The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure
por: Takaya, Hiroaki, et al.
Publicado: (2023)

Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
por: Moriya, Kei, et al.
Publicado: (2021)

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis
por: Namisaki, Tadashi, et al.
Publicado: (2017)

Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B
por: Tsuji, Yuki, et al.
Publicado: (2020)

Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2020)

ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability
por: Takaya, Hiroaki, et al.
Publicado: (2022)

Thyroid‐stimulating hormone is an independent risk factor of non‐alcoholic fatty liver disease
por: Tahara, Kazuki, et al.
Publicado: (2019)

Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2021)

Rifaximin enhances the L-carnitine-mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut-liver-muscle axis
por: Murata, Koji, et al.
Publicado: (2022)

Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells
por: Asada, Kiyoshi, et al.
Publicado: (2020)

Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis
por: Fujinaga, Yukihisa, et al.
Publicado: (2022)

VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis
por: Sato, Shinya, et al.
Publicado: (2021)

Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis
por: Sato, Shinya, et al.
Publicado: (2020)

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
por: Moriya, Kei, et al.
Publicado: (2019)

Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy
por: Ishida, Koji, et al.
Publicado: (2020)

Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis
por: Moriya, Kei, et al.
Publicado: (2021)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Clinical Significance of Gamma-Glutamyltranspeptidase Combined with Carbohydrate-Deficient Transferrin for the Assessment of Excessive Alcohol Consumption in Patients with Alcoholic Cirrhosis
por: Shibamoto, Akihiko, et al.
Publicado: (2021)

ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
por: Takaya, Hiroaki, et al.
Publicado: (2019)

Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis
por: Ogawa, Hiroyuki, et al.
Publicado: (2021)

Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model
por: Seki, Kenichiro, et al.
Publicado: (2018)

Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study
por: Nakanishi, Keisuke, et al.
Publicado: (2019)

DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis
por: Asada, Kiyoshi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vs2dab5mlff5m8cmlt2hf13l83